| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies.
|
Lancet
|
2002
|
16.56
|
|
2
|
A whole-genome association study of major determinants for host control of HIV-1.
|
Science
|
2007
|
15.19
|
|
3
|
Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies.
|
Lancet
|
2009
|
14.01
|
|
4
|
Inflammatory and coagulation biomarkers and mortality in patients with HIV infection.
|
PLoS Med
|
2008
|
13.72
|
|
5
|
Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study.
|
Arch Intern Med
|
2006
|
9.21
|
|
6
|
Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study.
|
Lancet
|
2005
|
6.60
|
|
7
|
Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort.
|
AIDS
|
2005
|
4.40
|
|
8
|
Morbidity and aging in HIV-infected persons: the Swiss HIV cohort study.
|
Clin Infect Dis
|
2011
|
4.31
|
|
9
|
Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies.
|
AIDS
|
2007
|
4.31
|
|
10
|
Common genetic variation and the control of HIV-1 in humans.
|
PLoS Genet
|
2009
|
3.68
|
|
11
|
Inflammation, coagulation and cardiovascular disease in HIV-infected individuals.
|
PLoS One
|
2012
|
3.68
|
|
12
|
Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy.
|
Clin Infect Dis
|
2005
|
3.57
|
|
13
|
Public-health and individual approaches to antiretroviral therapy: township South Africa and Switzerland compared.
|
PLoS Med
|
2008
|
3.56
|
|
14
|
CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study.
|
Arch Intern Med
|
2003
|
3.41
|
|
15
|
Cohort profile: the Swiss HIV Cohort study.
|
Int J Epidemiol
|
2009
|
3.05
|
|
16
|
Improved virological outcome in White patients infected with HIV-1 non-B subtypes compared to subtype B.
|
Clin Infect Dis
|
2011
|
2.98
|
|
17
|
A clinically prognostic scoring system for patients receiving highly active antiretroviral therapy: results from the EuroSIDA study.
|
J Infect Dis
|
2002
|
2.87
|
|
18
|
Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients.
|
AIDS
|
2010
|
2.85
|
|
19
|
Association of noncirrhotic portal hypertension in HIV-infected persons and antiretroviral therapy with didanosine: a nested case-control study.
|
Clin Infect Dis
|
2009
|
2.78
|
|
20
|
Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy.
|
J Infect Dis
|
2005
|
2.73
|
|
21
|
Spontaneous viral clearance, viral load, and genotype distribution of hepatitis C virus (HCV) in HIV-infected patients with anti-HCV antibodies in Europe.
|
J Infect Dis
|
2008
|
2.72
|
|
22
|
Serious fatal and nonfatal non-AIDS-defining illnesses in Europe.
|
J Acquir Immune Defic Syndr
|
2010
|
2.59
|
|
23
|
High prevalence of severe vitamin D deficiency in combined antiretroviral therapy-naive and successfully treated Swiss HIV patients.
|
AIDS
|
2010
|
2.49
|
|
24
|
Higher CNS penetration-effectiveness of long-term combination antiretroviral therapy is associated with better HIV-1 viral suppression in cerebrospinal fluid.
|
J Acquir Immune Defic Syndr
|
2013
|
2.38
|
|
25
|
Molecular epidemiology reveals long-term changes in HIV type 1 subtype B transmission in Switzerland.
|
J Infect Dis
|
2010
|
2.21
|
|
26
|
Changes in inflammatory and coagulation biomarkers: a randomized comparison of immediate versus deferred antiretroviral therapy in patients with HIV infection.
|
J Acquir Immune Defic Syndr
|
2011
|
2.21
|
|
27
|
Incidence and risk factors for chronic elevation of alanine aminotransferase levels in HIV-infected persons without hepatitis b or c virus co-infection.
|
Clin Infect Dis
|
2010
|
2.17
|
|
28
|
Frequency and determinants of unprotected sex among HIV-infected persons: the Swiss HIV cohort study.
|
Clin Infect Dis
|
2010
|
2.12
|
|
29
|
Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008.
|
Arch Intern Med
|
2010
|
2.05
|
|
30
|
The changing incidence of AIDS events in patients receiving highly active antiretroviral therapy.
|
Arch Intern Med
|
2005
|
1.97
|
|
31
|
Mortality in the Swiss HIV Cohort Study (SHCS) and the Swiss general population.
|
Lancet
|
2003
|
1.94
|
|
32
|
Modeling the influence of APOC3, APOE, and TNF polymorphisms on the risk of antiretroviral therapy-associated lipid disorders.
|
J Infect Dis
|
2005
|
1.93
|
|
33
|
Pulmonary arterial hypertension related to HIV infection: improved hemodynamics and survival associated with antiretroviral therapy.
|
Clin Infect Dis
|
2004
|
1.89
|
|
34
|
Migrants from Sub-Saharan Africa in the Swiss HIV Cohort Study: access to antiretroviral therapy, disease progression and survival.
|
AIDS
|
2003
|
1.87
|
|
35
|
The HIV care cascade in Switzerland: reaching the UNAIDS/WHO targets for patients diagnosed with HIV.
|
AIDS
|
2015
|
1.84
|
|
36
|
Transmission of HIV-1 drug resistance in Switzerland: a 10-year molecular epidemiology survey.
|
AIDS
|
2007
|
1.81
|
|
37
|
Stable virulence levels in the HIV epidemic of Switzerland over two decades.
|
AIDS
|
2006
|
1.81
|
|
38
|
Emergence of HIV-1 drug resistance in previously untreated patients initiating combination antiretroviral treatment: a comparison of different regimen types.
|
Arch Intern Med
|
2007
|
1.80
|
|
39
|
Durability and outcome of initial antiretroviral treatments received during 2000--2005 by patients in the Swiss HIV Cohort Study.
|
J Infect Dis
|
2008
|
1.76
|
|
40
|
Impact of occasional short interruptions of HAART on the progression of HIV infection: results from a cohort study.
|
AIDS
|
2002
|
1.75
|
|
41
|
Safe interruption of maintenance therapy against previous infection with four common HIV-associated opportunistic pathogens during potent antiretroviral therapy.
|
Ann Intern Med
|
2002
|
1.70
|
|
42
|
Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per microL in Europe and North America: a pooled cohort observational study.
|
Lancet
|
2010
|
1.69
|
|
43
|
Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes: a cohort study.
|
Lancet Infect Dis
|
2011
|
1.68
|
|
44
|
Influence of HIV-related immunodeficiency on the risk of hepatocellular carcinoma.
|
AIDS
|
2008
|
1.66
|
|
45
|
Role of retroviral restriction factors in the interferon-α-mediated suppression of HIV-1 in vivo.
|
Proc Natl Acad Sci U S A
|
2012
|
1.65
|
|
46
|
Ambiguous nucleotide calls from population-based sequencing of HIV-1 are a marker for viral diversity and the age of infection.
|
Clin Infect Dis
|
2011
|
1.64
|
|
47
|
Intermittent and sustained low-level HIV viral rebound in patients receiving potent antiretroviral therapy.
|
AIDS
|
2002
|
1.63
|
|
48
|
HIV cohort collaborations: proposal for harmonization of data exchange.
|
Antivir Ther
|
2004
|
1.53
|
|
49
|
Relationship between antiretrovirals used as part of a cART regimen and CD4 cell count increases in patients with suppressed viremia.
|
AIDS
|
2006
|
1.52
|
|
50
|
Effect of individual cognitive behaviour intervention on adherence to antiretroviral therapy: prospective randomized trial.
|
Antivir Ther
|
2004
|
1.51
|
|
51
|
Long-term trends of HIV type 1 drug resistance prevalence among antiretroviral treatment-experienced patients in Switzerland.
|
Clin Infect Dis
|
2009
|
1.50
|
|
52
|
ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir.
|
Pharmacogenet Genomics
|
2010
|
1.46
|
|
53
|
Association of pharmacogenetic markers with premature discontinuation of first-line anti-HIV therapy: an observational cohort study.
|
J Infect Dis
|
2010
|
1.45
|
|
54
|
Viral suppression rates in salvage treatment with raltegravir improved with the administration of genotypic partially active or inactive nucleoside/tide reverse transcriptase inhibitors.
|
J Acquir Immune Defic Syndr
|
2011
|
1.44
|
|
55
|
Neighbourhood socio-economic position, late presentation and outcomes in people living with HIV in Switzerland.
|
AIDS
|
2015
|
1.41
|
|
56
|
Switching from protease inhibitors to efavirenz: differences in efficacy and tolerance among risk groups: a case-control study from the Swiss HIV Cohort.
|
AIDS
|
2002
|
1.41
|
|
57
|
Clinical efficacy of early initiation of HAART in patients with asymptomatic HIV infection and CD4 cell count > 350 x 10(6) /l.
|
AIDS
|
2002
|
1.38
|
|
58
|
Virological rebound after suppression on highly active antiretroviral therapy.
|
AIDS
|
2003
|
1.34
|
|
59
|
HIV-1 coreceptor usage and CXCR4-specific viral load predict clinical disease progression during combination antiretroviral therapy.
|
AIDS
|
2008
|
1.34
|
|
60
|
Prevalence of comedications and effect of potential drug-drug interactions in the Swiss HIV Cohort Study.
|
Antivir Ther
|
2010
|
1.30
|
|
61
|
Is the virulence of HIV changing? A meta-analysis of trends in prognostic markers of HIV disease progression and transmission.
|
AIDS
|
2012
|
1.29
|
|
62
|
Factors associated with the development of opportunistic infections in HIV-1-infected adults with high CD4+ cell counts: a EuroSIDA study.
|
J Infect Dis
|
2006
|
1.28
|
|
63
|
HIV-1 p24 antigen is a significant inverse correlate of CD4 T-cell change in patients with suppressed viremia under long-term antiretroviral therapy.
|
J Acquir Immune Defic Syndr
|
2003
|
1.24
|
|
64
|
Systemic antibody responses to gut commensal bacteria during chronic HIV-1 infection.
|
Gut
|
2011
|
1.18
|
|
65
|
Incidence of HIV-1 drug resistance among antiretroviral treatment-naive individuals starting modern therapy combinations.
|
Clin Infect Dis
|
2011
|
1.17
|
|
66
|
Risk of AIDS and death at given HIV-RNA and CD4 cell count, in relation to specific antiretroviral drugs in the regimen.
|
AIDS
|
2005
|
1.16
|
|
67
|
Estimating loss to follow-up in HIV-infected patients on antiretroviral therapy: the effect of the competing risk of death in Zambia and Switzerland.
|
PLoS One
|
2011
|
1.15
|
|
68
|
Short-term clinical disease progression in HIV-1-positive patients taking combination antiretroviral therapy: the EuroSIDA risk-score.
|
AIDS
|
2007
|
1.15
|
|
69
|
Stratification of cumulative antibiograms in hospitals for hospital unit, specimen type, isolate sequence and duration of hospital stay.
|
J Antimicrob Chemother
|
2008
|
1.15
|
|
70
|
Triple-class virologic failure in HIV-infected patients undergoing antiretroviral therapy for up to 10 years.
|
Arch Intern Med
|
2010
|
1.12
|
|
71
|
Heterogeneity in outcomes of treated HIV-positive patients in Europe and North America: relation with patient and cohort characteristics.
|
Int J Epidemiol
|
2012
|
1.11
|
|
72
|
Treatment-naive individuals are the major source of transmitted HIV-1 drug resistance in men who have sex with men in the Swiss HIV Cohort Study.
|
Clin Infect Dis
|
2013
|
1.08
|
|
73
|
African descent is associated with slower CD4 cell count decline in treatment-naive patients of the Swiss HIV Cohort Study.
|
AIDS
|
2009
|
1.08
|
|
74
|
Changes in viral load in people with virological failure who remain on the same HAART regimen.
|
Antivir Ther
|
2003
|
1.04
|
|
75
|
Hepatitis C virus coinfection does not influence the CD4 cell recovery in HIV-1-infected patients with maximum virologic suppression.
|
J Acquir Immune Defic Syndr
|
2009
|
1.04
|
|
76
|
Thymidine analogue mutation profiles: factors associated with acquiring specific profiles and their impact on the virological response to therapy.
|
Antivir Ther
|
2005
|
1.03
|
|
77
|
Different patterns of inappropriate antimicrobial use in surgical and medical units at a tertiary care hospital in Switzerland: a prevalence survey.
|
PLoS One
|
2010
|
1.03
|
|
78
|
The role of migration and domestic transmission in the spread of HIV-1 non-B subtypes in Switzerland.
|
J Infect Dis
|
2011
|
1.03
|
|
79
|
Factors associated with the emergence of K65R in patients with HIV-1 infection treated with combination antiretroviral therapy containing tenofovir.
|
Clin Infect Dis
|
2008
|
1.02
|
|
80
|
Impact of previous virological treatment failures and adherence on the outcome of antiretroviral therapy in 2007.
|
PLoS One
|
2009
|
1.01
|
|
81
|
Causality, mediation and time: a dynamic viewpoint.
|
J R Stat Soc Ser A Stat Soc
|
2012
|
1.00
|
|
82
|
A sequential Cox approach for estimating the causal effect of treatment in the presence of time-dependent confounding applied to data from the Swiss HIV Cohort Study.
|
Stat Med
|
2010
|
1.00
|
|
83
|
HBV or HCV coinfections and risk of myocardial infarction in HIV-infected individuals: the D:A:D Cohort Study.
|
Antivir Ther
|
2010
|
1.00
|
|
84
|
Eligibility for and outcome of hepatitis C treatment of HIV-coinfected individuals in clinical practice: the Swiss HIV cohort study.
|
Antivir Ther
|
2006
|
0.99
|
|
85
|
Contribution of genome-wide significant single-nucleotide polymorphisms and antiretroviral therapy to dyslipidemia in HIV-infected individuals: a longitudinal study.
|
Circ Cardiovasc Genet
|
2009
|
0.99
|
|
86
|
A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection.
|
J Infect Dis
|
2002
|
0.99
|
|
87
|
Antiretroviral drug-related liver mortality among HIV-positive persons in the absence of hepatitis B or C virus coinfection: the data collection on adverse events of anti-HIV drugs study.
|
Clin Infect Dis
|
2012
|
0.98
|
|
88
|
Choice of Initial Combination Antiretroviral Therapy in Individuals With HIV Infection: Determinants and Outcomes.
|
Arch Intern Med
|
2012
|
0.98
|
|
89
|
Epidemiological and biological evidence for a compensatory effect of connection domain mutation N348I on M184V in HIV-1 reverse transcriptase.
|
J Infect Dis
|
2010
|
0.98
|
|
90
|
Correlation between case mix index and antibiotic use in hospitals.
|
J Antimicrob Chemother
|
2008
|
0.98
|
|
91
|
A standardized algorithm for determining the underlying cause of death in HIV infection as AIDS or non-AIDS related: results from the EuroSIDA study.
|
HIV Clin Trials
|
2011
|
0.98
|
|
92
|
HIV-1 reverse transcriptase connection domain mutations: dynamics of emergence and implications for success of combination antiretroviral therapy.
|
Clin Infect Dis
|
2010
|
0.97
|
|
93
|
Causes of death in HIV infection: the key determinant to define the clinical response to anti-HIV therapy.
|
AIDS
|
2004
|
0.96
|
|
94
|
A coronary heart disease risk model for predicting the effect of potent antiretroviral therapy in HIV-1 infected men.
|
Int J Epidemiol
|
2007
|
0.96
|
|
95
|
Impact of single nucleotide polymorphisms and of clinical risk factors on new‐onset diabetes mellitus in HIV‐infected individuals.
|
Clin Infect Dis
|
2010
|
0.94
|
|
96
|
Association of virus load, CD4 cell count, and treatment with clinical progression in human immunodeficiency virus-infected patients with very low CD4 cell counts.
|
J Infect Dis
|
2002
|
0.93
|
|
97
|
Risk factors for and outcome of hyperlactatemia in HIV-infected persons: is there a need for routine lactate monitoring?
|
Clin Infect Dis
|
2005
|
0.93
|
|
98
|
Impact of lamivudine on the risk of liver-related death in 2,041 HBsAg- and HIV-positive individuals: results from an inter-cohort analysis.
|
Antivir Ther
|
2006
|
0.92
|
|
99
|
Cobas ampliprep/cobas TaqMan HIV-1 v2.0 assay: consequences at the cohort level.
|
PLoS One
|
2013
|
0.90
|
|
100
|
Baseline resistance and virological outcome in patients with virological failure who start a regimen containing abacavir: EuroSIDA study.
|
Antivir Ther
|
2004
|
0.89
|
|
101
|
Outcomes of antiretroviral therapy in the Swiss HIV Cohort Study: latent class analysis.
|
AIDS Behav
|
2012
|
0.89
|
|
102
|
Effects of alpha interferon treatment on intrinsic anti-HIV-1 immunity in vivo.
|
J Virol
|
2013
|
0.89
|
|
103
|
Effects of cognitive behavioral stress management on HIV-1 RNA, CD4 cell counts and psychosocial parameters of HIV-infected persons.
|
AIDS
|
2008
|
0.88
|
|
104
|
Effect of acetazolamide and autoCPAP therapy on breathing disturbances among patients with obstructive sleep apnea syndrome who travel to altitude: a randomized controlled trial.
|
JAMA
|
2012
|
0.87
|
|
105
|
Implementation of raltegravir in routine clinical practice: selection criteria for choosing this drug, virologic response rates, and characteristics of failures.
|
J Acquir Immune Defic Syndr
|
2010
|
0.87
|
|
106
|
Antiretroviral treatment and osteonecrosis in patients of the Swiss HIV Cohort Study: a nested case-control study.
|
AIDS Res Hum Retroviruses
|
2004
|
0.87
|
|
107
|
CD4 cell count and viral load-specific rates of AIDS, non-AIDS and deaths according to current antiretroviral use.
|
AIDS
|
2013
|
0.86
|
|
108
|
Long-lasting protection of activity of nucleoside reverse transcriptase inhibitors and protease inhibitors (PIs) by boosted PI containing regimens.
|
PLoS One
|
2012
|
0.86
|
|
109
|
Estimated average annual rate of change of CD4(+) T-cell counts in patients on combination antiretroviral therapy.
|
Antivir Ther
|
2010
|
0.86
|
|
110
|
Minor protease inhibitor mutations at baseline do not increase the risk for a virological failure in HIV-1 subtype B infected patients.
|
PLoS One
|
2012
|
0.85
|
|
111
|
Higher risk of incident hepatitis C virus coinfection among men who have sex with men, in whom the HIV genetic bottleneck at transmission was wide.
|
J Infect Dis
|
2014
|
0.85
|
|
112
|
Long-term exposure to combination antiretroviral therapy and risk of death from specific causes: no evidence for any previously unidentified increased risk due to antiretroviral therapy.
|
AIDS
|
2012
|
0.85
|
|
113
|
Predictors of CD4(+) T-cell counts of HIV type 1-infected persons after virologic failure of all 3 original antiretroviral drug classes.
|
J Infect Dis
|
2012
|
0.84
|
|
114
|
Impact of genotypic resistance testing on selection of salvage regimen in clinical practice.
|
Antivir Ther
|
2003
|
0.84
|
|
115
|
Cost-effectiveness of genotypic antiretroviral resistance testing in HIV-infected patients with treatment failure.
|
PLoS One
|
2007
|
0.84
|
|
116
|
Risk factors for urinary tract infections due to ciprofloxacin-resistant Escherichia coli in a tertiary care urology department in Switzerland.
|
Swiss Med Wkly
|
2010
|
0.83
|
|
117
|
Co-trimoxazole prophylaxis is associated with reduced risk of incident tuberculosis in participants in the Swiss HIV Cohort Study.
|
Antimicrob Agents Chemother
|
2014
|
0.83
|
|
118
|
Are specific antiretrovirals associated with an increased risk of discontinuation due to toxicities or patient/physician choice in patients with hepatitis C virus coinfection?
|
Antivir Ther
|
2005
|
0.82
|
|
119
|
Analyzing direct and indirect effects of treatment using dynamic path analysis applied to data from the Swiss HIV Cohort Study.
|
Stat Med
|
2011
|
0.82
|
|
120
|
Noncirrhotic portal hypertension and didanosine: a re-analysis.
|
Clin Infect Dis
|
2011
|
0.81
|
|
121
|
Dose-dependent influence of didanosine on immune recovery in HIV-infected patients treated with tenofovir.
|
AIDS
|
2005
|
0.81
|
|
122
|
Calendar time trends in the incidence and prevalence of triple-class virologic failure in antiretroviral drug-experienced people with HIV in Europe.
|
J Acquir Immune Defic Syndr
|
2012
|
0.81
|
|
123
|
Accounting for baseline differences and measurement error in the analysis of change over time.
|
Stat Med
|
2013
|
0.81
|
|
124
|
CD4/CD8 ratio and CD8 counts predict CD4 response in HIV-1-infected drug naive and in patients on cART.
|
Medicine (Baltimore)
|
2016
|
0.81
|
|
125
|
A longitudinal analysis of healthcare costs after treatment optimization following genotypic antiretroviral resistance testing: does resistance testing pay off?
|
Antivir Ther
|
2006
|
0.80
|
|
126
|
Long-term virological response to multiple sequential regimens of highly active antiretroviral therapy for HIV infection.
|
Antivir Ther
|
2004
|
0.80
|
|
127
|
Long-term efficacy after switch from protease inhibitor-containing highly active antiretroviral therapy to abacavir, lamivudine, and zidovudine.
|
AIDS
|
2004
|
0.79
|
|
128
|
No longitudinal mitochondrial DNA sequence changes in HIV-infected individuals with and without lipoatrophy.
|
J Infect Dis
|
2011
|
0.78
|
|
129
|
Polymorphic mutations associated with the emergence of the multinucleoside/tide resistance mutations 69 insertion and Q151M.
|
J Acquir Immune Defic Syndr
|
2012
|
0.78
|
|
130
|
Predictors for the emergence of the 2 multi-nucleoside/nucleotide resistance mutations 69 insertion and Q151M and their impact on clinical outcome in the Swiss HIV cohort study.
|
J Infect Dis
|
2011
|
0.77
|
|
131
|
Rate of viral rebound according to specific drugs in the regimen in 2120 patients with HIV suppression.
|
AIDS
|
2004
|
0.76
|
|
132
|
Predictive cross-validation for the choice of linear mixed-effects models with application to data from the Swiss HIV Cohort Study.
|
Biometrics
|
2011
|
0.76
|
|
133
|
Response to Calcagno comment on "Higher CNS penetration-effectiveness of long-term combination antiretroviral therapy is associated with better HIV-1 viral suppression in cerebrospinal fluid".
|
J Acquir Immune Defic Syndr
|
2013
|
0.75
|